keyword
MENU ▼
Read by QxMD icon Read
search

braf performance

keyword
https://www.readbyqxmd.com/read/27911099/nuclear-morphometric-findings-in-undetermined-cytology-a-possible-clue-for-prediction-of-braf-mutation-in-papillary-thyroid-carcinomas
#1
Sevdegul Mungan, Safak Ersoz, Ismail Saygin, Zeynep Sagnak, Umit Cobanoglu
PURPOSE: To investigate the possible relationship between the nuclear morphometric characteristics (nuclear perimeter, roundness, nuclear area, and nuclear shape) and BRAF mutation status in papillary thyroid carcinoma cases with a prior diagnosis of undetermined cytology. MATERIALS AND METHODS: Total thyroidectomy specimens obtained from 48 patients with papillary thyroid carcinoma with a prior diagnosis of undetermined cytology were included. Morphometric analysis under light microscopy included measurements of the perimeter, shape factor, nuclear area, and roundness of thyrocyte nuclei from the cytological smear preparations...
December 2, 2016: Endocrine Research
https://www.readbyqxmd.com/read/27885401/-cutaneous-side-effects-of-targeted-cancer-drugs
#2
REVIEW
J Below, B Homey, P A Gerber
In the past decades many new drugs were approved for the treatment of cancer and have been established as essential parts of various therapeutic regimens. In particular targeted therapies and immune checkpoint inhibitors that aim at specific carcinogenic signaling pathways or modulate the tumor-immune response have revolutionized cancer therapy. Despite their targeted actions, these drugs may lead to diverse adverse reactions. In particular, cutaneous toxicities represent a serious threat to patients' quality of life and may lead to dose reduction or therapy cessation...
November 24, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27879568/effect-of-immunotherapy-status-on-outcomes-in-patients-with-metastatic-melanoma-to-the-spine
#3
Ganesh M Shankar, Bryan D Choi, Benjamin L Grannan, Kevin Oh, John H Shin
STUDY DESIGN: Retrospective cohort study OBJECTIVE.: We performed a retrospective study of patients treated at our institution over the last 3 years to assess predictive value of immunotherapy exposure on overall survival of patients with metastatic melanoma to the spine in an effort to better inform surgical decision making. SUMMARY OF BACKGROUND DATA: Modern management of metastatic melanoma includes adjuvant targeted therapies and immunomodulators that have shown to significantly improve overall survival...
November 22, 2016: Spine
https://www.readbyqxmd.com/read/27877056/a-retrospective-analysis-of-the-clinicopathological-and-molecular-characteristics-of-pulmonary-blastoma
#4
Yuan-Yuan Zhao, Lin Liu, Ting Zhou, Ning-Ning Zhou, Yun-Peng Yang, Xue Hou, Yong Li, Hong-Yun Zhao, Yan Huang, Li Zhang
PURPOSE: The aim of this study was to analyze and summarize the clinicopathological and molecular characteristics of classic biphasic pulmonary blastoma (PB) to improve its diagnosis and treatment. PATIENTS AND METHODS: A retrospective analysis was performed in patients who were diagnosed with PB at Sun Yat-Sen University Cancer Center from March 1995 to March 2015. Genomic DNA was profiled using a capture-based targeted sequencing panel. RESULTS: Sixteen patients with an average age of 40 years were included in this study...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27856123/prognostic-impact-of-primary-tumor-location-on-clinical-outcomes-of-metastatic-colorectal-cancer-treated-with-cetuximab-plus-oxaliplatin-based-chemotherapy-a-subgroup-analysis-of-the-jaccro-cc-05-06-trials
#5
Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
INTRODUCTION: Primary tumor location is a critical prognostic factor in metastatic colorectal cancer (mCRC); however, it remains unclear whether tumor location is a predictor of the response to cetuximab treatment. It is also uncertain if BRAF mutation contributes to the impact of tumor location on survival. We assessed the prognostic impact of tumor location on clinical outcomes in mCRC patients treated with first-line cetuximab chemotherapy. PATIENTS AND METHODS: The associations of tumor location with overall survival and progression-free survival were evaluated in mCRC patients with KRAS exon 2 wild-type tumors who were enrolled onto 2 clinical trials: JACCRO CC-05 of cetuximab plus FOLFOX (n = 57, UMIN000004197) and CC-06 of cetuximab plus SOX (n = 61, UMIN000007022)...
October 6, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27855847/p15-expression-differentiates-nevus-from-melanoma
#6
Laura A Taylor, Conor O'Day, Tzvete Dentchev, Kyle Hood, Emily Y Chu, Todd W Ridky, John T Seykora
Most melanomas are driven by BRAF(V600E)-activating mutations, while nevi harboring the same mutations have growth arrest. Although decreased p16 expression has been associated with melanoma formation, in recent work, p15 represented a primary effector of oncogene-induced senescence in nevomelanocytes that was diminished in melanomas. This study determined whether decreased p15 levels represent a general biomarker for the transition from nevus to melanoma. We performed p15 and p16 IHC analyses on a random series of nevi and melanomas...
December 2016: American Journal of Pathology
https://www.readbyqxmd.com/read/27852040/clinical-validation-of-prospective-liquid-biopsy-monitoring-in-patients-with-wild-type-ras-metastatic-colorectal-cancer-treated-with-folfiri-cetuximab
#7
Rodrigo A Toledo, Antonio Cubillo, Estela Vega, Elena Garralda, Rafael Alvarez, Lisardo U de la Varga, Jesús R Pascual, Gema Sánchez, Francesca Sarno, Susana H Prieto, Sofía Perea, Pedro P Lopéz-Casas, Fernando López-Ríos, Manuel Hidalgo
Cancer genomics and translational medicine rely on the molecular profiling of patient's tumor obtained during surgery or biopsy. Alternatively, blood is a less invasive source of tumor DNA shed, amongst other ways, as cell-free DNA (cfDNA). Highly-sensitive assays capable to detect cancer genetic events from patient's blood plasma became popularly known as liquid biopsy (LqB). Importantly, retrospective studies including small number of selected patients with metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapy have shown LqB capable to detect the acquired clonal mutations in RAS genes leading to therapy resistance...
November 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27833932/targeted-treatment-of-brainstem-neurohistiocytosis-guided-by-urinary-cell-free-dna
#8
David Hunt, Paul Milne, Peter Fernandes, Venetia Bigley, Matthew Collin
OBJECTIVE: To identify a treatment-responsive BRAF(V600E) mutation in brainstem neurohistiocytosis, where no lesional tissue was readily obtainable, using a cell-free DNA approach. METHODS: Cell-free DNA was extracted from urine and allele-specific PCR for the BRAF(V600E) mutation was performed. Response to conventional treatment (corticosteroids and interferon) and targeted treatment with a BRAF inhibitor was assessed by clinical evaluation, gadolinium-enhanced MRI brain scan, and serial testing of urinary cell-free DNA for mutant alleles...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27833153/tert-promoter-mutation-and-its-association-with-clinicopathological-features-and-prognosis-of-papillary-thyroid-cancer-a-meta-analysis
#9
Chunping Liu, Zeming Liu, Tianwen Chen, Wen Zeng, Yawen Guo, Tao Huang
We performed a meta-analysis to elucidate the associations of the clinicopathological characteristics and prognostic factors of papillary thyroid cancer (PTC) with TERT promoter mutations. A literature search was performed of the PubMed and EMBASE databases using Medical Subject Headings and keywords. Individual study-specific odds ratios (ORs) and confidence intervals (CIs) were calculated. The average prevalence rate of TERT promoter mutations was 10.1%. TERT promoter mutations occurred more frequently in patients with larger tumors (p = 0...
November 11, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27822597/melanoma-brain-metastases-correlation-of-imaging-features-with-genomic-markers-and-patient-survival
#10
Ritu Bordia, Hua Zhong, Joon Lee, Sarah Weiss, Sung Won Han, Iman Osman, Rajan Jain
Purpose To identify MR imaging features of melanoma brain metastases (MBM) that correlate with genetic profile of melanoma and patient survival. Materials and methods Patients with newly diagnosed melanoma metastases were identified from institutional database A retrospective review of brain MRI was performed focusing on lesion number, size, T1-, T2- and diffusion-weighted signal characteristics, hemorrhage, necrosis, enhancement pattern and edema. Genomic (BRAF status), treatment and survival data was collected...
November 7, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27821299/biomarkers-related-with-seizure-risk-in-glioma-patients-a-systematic-review
#11
REVIEW
Xing-Wang Zhou, Xiang Wang, Yuan Yang, Jie-Wen Luo, Hui Dong, Yan-Hui Liu, Qing Mao
Increasing evidence indicates that genetic biomarkers play important roles in the development of glioma-associated seizures. Thus, we performed a systematic review to summarise biomarkers that are associated with seizures in glioma patients. An electronic literature search of public databases (PubMed, Embase and Medline) was performed using the keywords glioma, seizure and epilepsy. A totall of 26 eligible studies with 2224 cases were included in this systematic review of publications to 20 June, 2016. Genetic biomarkers such as isocitrate dehydrogenase 1 (IDH1) mutations, low expression of excitatory amino acid transporter 2 (EAAT2), high xCT expression, overexpression of adenosine kinase (ADK) and low expression of very large G-protein-coupled receptor-1 (VLGR1) are primarily involved in synaptic transmission, whereas BRAF mutations, epidermal growth factor receptor (EGFR) amplification, miR-196b expression and low ki-67 expression are associated with regulation of cell proliferation...
December 2016: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/27816346/-neuro-langerhans-cell-histiocytosis
#12
Loïc Le Guennec, Nadine Martin-Duverneuil, Karima Mokhtari, Maria Santiago-Ribeiro, Eléonore Bayen, Antoine Del Cul, Daniel Delgadillo, Aurélie Kas, Carine Courtillot, Julien Haroche, Fleur Cohen, Jean Donadieu, Khê Hoang-Xuan, Ahmed Idbaih
Langerhans cell histiocytosis (LCH) is a rare multisystemic disease. LCH is characterized by proliferation of myeloid progenitors with altered differentiation program and similar phenotypic features to epidermal dendritic cells termed Langerhans cell. LCH cells express CD1a+ and langerin and exhibit BRAF V600E mutation in ∼50% of cases. Neurological involvement or neuro-LCH is observed in 5 to 10% of cases. Three subtypes of neuro-LCH are individualized. The tumor type, accounting for 45% of neuro-LCH, affect mainly young adults...
November 2, 2016: La Presse Médicale
https://www.readbyqxmd.com/read/27799506/personalized-treatment-for-a-patient-with-a-braf-v600e-mutation-using-dabrafenib-and-a-tumor-treatment-fields-device-in-a-high-grade-glioma-arising-from-ganglioglioma
#13
Silviya K Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A Elvin, Norma Palma, Jeffrey S Ross, Vincent A Miller, Philip J Stephens, George Snipes, Veena Rajaram, Siraj M Ali, Isaac Melguizo-Gavilanes
BACKGROUND: Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However, some patients will experience tumor recurrence and/or malignant progression. This article reports on the clinical history, molecular findings, and treatment response in a patient with BRAF V600-mutated high-grade glioma arising from ganglioglioma. METHODS: Hematoxylin-eosin staining and comprehensive genomic profiling via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27798894/kras-mutant-status-p16-and-%C3%AE-catenin-expression-may-predict-local-recurrence-in-patients-who-underwent-transanal-endoscopic-microsurgery-tems-for-stage-i-rectal-cancer
#14
Michail Sideris, Jane Moorhead, Salvador Diaz-Cano, Ingvar Bjarnason, Amyn Haji, Savvas Papagrigoriadis
BACKGROUND/AIM: Transanal endoscopic microsurgery (TEMS) is emerging as an alternative treatment for rectal cancer Stage I. There remains a risk of local recurrence. The Aim of the study was to study the effect of biomarkers in local recurrence for Stage I rectal cancer following TEMS plus or minus radiotherapy. MATERIALS AND METHODS: This is a case control study where we compared 10 early rectal cancers that had recurred, against 19 cases with no recurrence, total 29 patients (age=28...
October 2016: Anticancer Research
https://www.readbyqxmd.com/read/27797976/genomic-heterogeneity-and-exceptional-response-to-dual-pathway-inhibition-in-anaplastic-thyroid-cancer
#15
William J Gibson, Daniel T Ruan, Vera A Paulson, Justine A Barletta, Glenn J Hanna, Stefan Kraft, Antonio Calles, Matthew A Nehs, Francis D Moore, Amaro Taylor-Weiner, Jeremiah A Wala, Travis I Zack, Thomas C Lee, Fiona M Fennessy, Erik K Alexander, Tom Tomas, Pasi A Janne, Levi A Garraway, Scott L Carter, Rameen Beroukhim, Jochen H Lorch, Eliezer Van Allen
PURPOSE: Cancers may resist single-agent targeted therapies when the flux of cellular growth signals is shifted from one pathway to another. Blockade of multiple pathways may be necessary for effective inhibition of tumor growth. We document a case in which a patient with anaplastic thyroid carcinoma (ATC) failed to respond to either mTOR or combined RAF/MEK inhibition, but experienced a dramatic response when both drug regimens were combined. EXPERIMENTAL DESIGN: Multi-region whole-exome sequencing of five diagnostic and four autopsy tumor biopsies was performed...
October 17, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27793009/the-changing-characteristics-and-molecular-profiles-of-papillary-thyroid-carcinoma-over-time-a-systematic-review
#16
REVIEW
Huy Gia Vuong, Ahmed M A Altibi, Amr Hesham Abdelhamid, Phuong Uyen Duong Ngoc, Vo Duy Quan, Mohamed Yousef Tantawi, Mohamed Elfil, Tran Le Huy Vu, Ahmed Elgebaly, Naoki Oishi, Tadao Nakazawa, Kenji Hirayama, Ryohei Katoh, Nguyen Tien Huy, Tetsuo Kondo
BACKGROUND: The genetic alterations of papillary thyroid carcinoma (PTC) have been reported to change over the past few decades. We performed this systematic review to further examine the trends and modifications of patient demographic, clinicopathological features and molecular profiles of PTC over time. METHODS: A literature search was performed within six electronic databases to identify relevant articles. The inclusion criteria were published studies investigating BRAF mutations, RET/PTC rearrangements or RAS mutations in PTCs or classical PTCs...
October 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27792249/a-comprehensive-analysis-identifies-braf-hotspot-mutations-associated-with-gliomas-with-peculiar-epithelial-morphology
#17
Ryusuke Hatae, Nobuhiro Hata, Satoshi O Suzuki, Koji Yoshimoto, Daisuke Kuga, Hideki Murata, Yojiro Akagi, Yuhei Sangatsuda, Toru Iwaki, Masahiro Mizoguchi, Koji Iihara
Brain tumors harbor various BRAF alterations, the vast majority of which are the BRAF kinase-activating V600E mutation. BRAF mutations are most frequently detected in certain subtypes of low-grade glioma, such as pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA), ganglioglioma (GG) and dysembryoplastic neuroepithelial tumor (DNT). However, it is unclear whether gliomas harboring BRAF mutations can be invariably regarded as these glioma subtypes or their derivatives. To address this question, we analyzed 274 gliomas in our institutional case series...
October 28, 2016: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/27790766/association-between-dermoscopic-and-reflectance-confocal-microscopy-features-of-cutaneous-melanoma-with-braf-mutational-status
#18
C Bombonato, S Ribero, F C Pozzobon, J A Puig-Butille, C Badenas, C Carrera, J Malvehy, E Moscarella, A Lallas, S Piana, S Puig, G Argenziano, C Longo
BACKGROUND: Melanomas harbouring common genetic mutations might share certain morphological features detectable with dermoscopy and reflectance confocal microscopy. BRAF mutational status is crucial for the management of metastatic melanoma. OBJECTIVES: To correlate the dermoscopic characteristics of primary cutaneous melanomas with BRAF mutational status. Furthermore, a subset of tumours has also been analysed for the presence of possible confocal features that might be linked with BRAF status...
October 28, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27787543/systemic-therapy-for-previously-untreated-advanced-braf-mutated-melanoma-a-systematic-review-and-network-meta-analysis-of-randomized-clinical-trials
#19
Tahira Devji, Oren Levine, Binod Neupane, Joseph Beyene, Feng Xie
Importance: Multiple effective first-line systemic treatment options are available for patients with advanced BRAF-mutated melanoma. A lack of head-to-head randomized clinical trials (RCTs) comparing targeted and immunotherapies leaves uncertainty regarding optimal first-line treatment. Objective: To estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-mutated melanoma. Data Sources: We searched MEDLINE, Embase, and the Cochrane Central Registry of Controlled Trials for phase 2 or 3 RCTs published up until April 29, 2016...
October 27, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27783987/the-combination-of-mln2238-ixazomib-with-interferon-alpha-results-in-enhanced-cell-death-in-melanoma
#20
Lorena P Suarez-Kelly, Gregory M Kemper, Megan C Duggan, Andrew Stiff, Tiffany C Nole, Joseph Markowitz, Eric A Luedke, Vedat O Yildiz, Lianbo Yu, Alena Cristina Jaime-Ramirez, Volodymyr Karpa, Xiaoli Zhang, William E Carson
The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib. Interferon-alpha (IFN-α), an immune boosting agent, is FDA-approved for treatment of melanoma. In this study in vitro and in vivo evaluation of the antitumor potential of ixazomib and combination treatments with ixazomib and IFN-α were performed...
October 21, 2016: Oncotarget
keyword
keyword
15664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"